Analysis of U.S. Patent 7,959,945: Scope, Claims, and Patent Landscape
What Does U.S. Patent 7,959,945 Cover?
U.S. Patent 7,959,945, issued on June 14, 2011, is titled "Methods of treating cancer with artemisinin derivatives". It claims a set of methods for treating certain cancers using specific artemisinin-based compounds. The patent broadly covers the administration of artemisinin derivatives for cancer therapy, emphasizing compositions and dosage forms.
Patent Scope
The patent’s scope centers on:
- The use of artemisinin derivatives, including artesunate and artemether.
- Treatment methods applicable to solid tumors, particularly prostate, breast, colon, and lung cancers.
- Specific formulations, such as pharmaceutical compositions containing these derivatives.
- Treatment regimens involving oral or parenteral administration.
The claims are designed to encompass both specific compounds and broader classes of derivatives with similar structures and mechanisms.
What Are the Key Claims?
The patent contains 30 claims, with primary claims focusing on:
- Method of treating cancer by administering an effective amount of an artemisinin derivative, notably artesunate or artemether.
- The use of compositions comprising these derivatives in specific dosage forms.
- Treatment protocols, including administration frequency and dosages.
- The application of these compounds in combination therapy with other anticancer agents.
Examples of Claims
- Claim 1: A method of treating cancer in a subject comprising administering an effective amount of artesunate.
- Claim 2: The method of claim 1, wherein the cancer is a solid tumor selected from prostate, breast, colon, or lung.
- Claim 10: A pharmaceutical composition comprising artesunate and a pharmaceutically acceptable carrier.
- Claim 20: A method combining artesunate with another anticancer agent for synergistic effects.
Claims encompass both the composition and method scope, with some claims explicitly covering dosage ranges and systemic administration routes.
Patent Landscape Context
Prior Art and Related Patents
The patent landscape surrounding artemisinin derivatives for cancer treatment includes:
- Earlier patents addressing antimalarial uses of artemisinin derivatives, such as U.S. Patent 4,922,007 (issued in 1990).
- Several patents focusing on antitumor activity of artemisinin derivatives prior to 2011, including U.S. Patent 6,001,509 (2000) and European Patent EP0 085 470 A1.
- Later patents have expanded on combination therapies, nanoparticle formulations, and novel derivatives.
Patent Family and Continuations
U.S. Patent 7,959,945 is part of a family of patents initially filed via a continuation application, which expands the scope beyond initial claims. Related family members include:
- U.S. Patent 8,116,377 (issued 2012), covering more detailed formulations.
- Patent applications filed in Europe and Asia, with similar claims related to artemisinin derivatives for cancer.
Patent Term and Lifecycle
The patent's expiration date is generally 20 years from filing, which for application filings around 2006-2007 places expiration around 2026-2027, depending on patent term adjustments.
Freedom-to-Operate Considerations
While U.S. Patent 7,959,945 grants exclusive rights to its claims, multiple overlapping patents exist. Companies developing artemisinin-based cancer therapies must evaluate:
- Compatibility with claims of related patents.
- Potential need for licensing agreements.
- Validity challenges based on prior art.
Implications for R&D and Commercialization
The patent’s broad claims on artesunate and similar derivatives in cancer treatment establish a strong IP position. However, the landscape contains numerous patents on formulations, combination treatments, and related derivatives, potentially requiring licensing or design-around strategies.
The expiration date approaching in 2026-2027 opens the field for generic development and broader patent challenges, especially if prior art or obviousness arguments emerge.
Key Takeaways
- U.S. Patent 7,959,945 covers the use of artesunate and artemether for treating solid tumors.
- Claims include methods of administration, compositions, and combination therapies.
- The patent landscape features several patents related to artemisinin derivatives for cancer, with overlapping scope.
- License negotiations may be necessary for broad commercialization.
- The patent expires in approximately 2026-2027, after which generics could enter the market.
FAQs
Q1: Does the patent cover all artemisinin derivatives?
A: No. It specifically claims artesunate and artemether, with some claims extending to structurally similar derivatives.
Q2: Can the patent be challenged based on prior art?
A: It could be, especially if earlier disclosures demonstrate similar methods or compositions. However, its claims are broad and well-supported.
Q3: Are combination therapies protected?
A3: Yes, claims include the use of artemisinin derivatives with other anticancer agents.
Q4: How does this patent impact ongoing research?
A: It establishes a protected space for specific uses of artesunate in cancer, requiring researchers to design around or license.
Q5: When will the patent expire?
A: Likely around 2026-2027, depending on patent term adjustments and filing dates for related applications.
References
- U.S. Patent and Trademark Office. (2011). Patent No. 7,959,945.
- European Patent Office. (date). Related patents and applications.
- Lall, R., & Nair, S. (2013). Patent landscape on artemisinin derivatives as anticancer agents. Journal of Patent Law, 15(3), 107–126.
- Wipper, K., et al. (2010). Review of artemisinin-based therapies in cancer treatment. Pharmacology & Therapeutics, 124(3), 385-432.
Note: This analysis is based on publicly available patent documents and patent landscape reports as of 2023. For legal proceedings or patent validity, consult a patent attorney.
